Tag
This article reviews a multicenter study comparing outcomes of different treatment approaches for gastric cancer patients with positive peritoneal cytology (CY1) and/or localized peritoneal metastasis (P1a), highlighting the superior surviv
The NEONIPIGA phase 2 trial demonstrates durable survival and high pathological complete response rates with neoadjuvant nivolumab and ipilimumab in localized MSI-high gastric and GEJ adenocarcinoma, highlighting potential for organ-preserv
This study validates the Critical View of Quality (CVQ) as an intraoperative metric of lymphadenectomy quality in distal gastrectomy and presents a novel computer vision model for its automated video-based assessment, enhancing objective su
This review summarizes the clinical characteristics, disease course, and survival outcomes of lung metastases after gastrectomy in gastric cancer patients, highlighting prognostic factors and the role of pulmonary metastasectomy.
This study elucidates transcriptomic differences between primary gastric cancers and peritoneal metastases, revealing distinct tumor microenvironments and molecular pathways, highlighting potential targets for improved diagnosis and therapy
Genomic alterations in primary gastric tumors, including KRAS and PIK3CA mutations, correlate with recurrence risk and metastatic patterns, informing personalized postoperative surveillance and treatment strategies.
SOX9 is a pivotal regulator of SPEM cell plasticity driving gastric metaplasia and carcinogenesis. Therapeutically targeting SOX9 may prevent the progression of pre-cancerous lesions to gastric cancer by blocking metaplastic evolution.
A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.
A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.
A nationwide Dutch cohort confirms that patients with FAP remain at markedly elevated risk for multiple gastrointestinal and extraintestinal cancers, with gastric cancer emerging as the most frequently diagnosed malignancy since 2020.
A retrospective study reveals robotic gastrectomy achieves higher textbook outcome rates than laparoscopic and open surgery, correlating with improved 1-year survival in gastric cancer patients.
This review synthesizes evidence from the GISSG+2201 trial and related studies, demonstrating that supervised multimodal prehabilitation significantly reduces postoperative complications and enhances functional recovery in older, frail pati
Researchers utilized spatial transcriptomics to uncover how HER2-positive gastric cancers evolve resistance to trastuzumab and T-DXd, identifying EMT, ERAD pathways, and metabolic shifts as key survival mechanisms that could inform future s
An international multicentre study of 1,240 patients reveals that autoimmune gastritis presentation varies by region, with distinct risk factors—including age, intestinal metaplasia, and extreme hypergastrinemia—driving the development of g
A randomized controlled trial demonstrates that early interactive human coaching via a mobile app improves long-term quality of life, reduces dyspnea, and eases eating restrictions in postgastrectomy patients, particularly among younger and
A phase 1b/2 trial reveals that combining the bispecific antibody zanidatamab with tislelizumab and chemotherapy yields a 75.8% response rate and an impressive median overall survival of 32.4 months in first-line HER2-positive gastric and g
A Cochrane review of nine RCTs (829 patients) found low‑certainty signals that intraperitoneal chemotherapy (mainly HIPEC) may improve overall survival in high‑risk and metastatic gastric cancer, but evidence is very uncertain due to bias,
The UMC‑UPPERGI‑01 randomized trial (n=208) found laparoscopic distal gastrectomy with D2 lymphadenectomy had similar 30‑day morbidity and mortality to open surgery for clinical T4a gastric cancer, despite longer operative times and modestl
A phase 2 arm of the EDGE‑Gastric trial reports a 59% confirmed objective response rate and median PFS 12.9 months with domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX in untreated HER2‑negative advanced gastric
In a phase 2 cohort (EDGE‑Gastric A1), domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX produced a 59% ORR, median PFS 12.9 months and median OS 26.7 months in 41 previously untreated HER2‑negative gastroesophage
